Regulus Therapeutics Inc.
General ticker "RGLS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $120.8M (TTM average)
Regulus Therapeutics Inc. follows the US Stock Market performance with the rate: 12.6%.
Estimated limits based on current volatility of 1.1%: low 8.00$, high 8.18$
Factors to consider:
- Company does not operate outside North America (retrieved using AI)
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.14$, 3.08$]
- 2025-12-31 to 2026-12-31 estimated range: [0.74$, 2.13$]
Financial Metrics affecting the RGLS estimates:
- Negative: Non-GAAP EPS, $ of -0.87 <= 0.05
- Negative: Operating cash flow per share per price, % of -31.72 <= 1.99
- Negative: Operating profit margin, % of -100 <= 0.04
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -24.73 <= 0
- Negative: Shareholder equity ratio, % of 90.77 > 63.58
- Negative: Industry operating profit margin (median), % of -98.39 <= 0.07
- Negative: 0 < Interest expense per share, $ of 0
- Negative: Investing cash flow per share, $ of -0.64 <= -0.10
Short-term RGLS quotes
Long-term RGLS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $28.24MM | $31.11MM | $50.04MM |
| Operating Income | $-28.24MM | $-31.11MM | $-50.04MM |
| Non-Operating Income | $-0.08MM | $1.07MM | $3.68MM |
| Interest Expense | $0.69MM | $0.60MM | $0.16MM |
| R&D Expense | $18.41MM | $21.15MM | $35.37MM |
| Income(Loss) | $-28.32MM | $-30.04MM | $-46.36MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-28.32MM | $-30.04MM | $-46.36MM |
| Stockholders Equity | $33.29MM | $21.19MM | $76.41MM |
| Inventory | $0.00MM | $3.01MM | $0.00MM |
| Assets | $46.72MM | $30.75MM | $84.18MM |
| Operating Cash Flow | $-25.53MM | $-26.77MM | $-41.67MM |
| Capital expenditure | $0.36MM | $0.61MM | $0.34MM |
| Investing Cash Flow | $-15.12MM | $14.49MM | $-35.98MM |
| Financing Cash Flow | $4.49MM | $11.82MM | $92.42MM |
| Earnings Per Share** | $-1.86 | $-1.58 | $-0.82 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.